Harpoon Therapeutics

General Information


We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using our proprietary TriTAC platform, we are developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.

Employees: 45
Founded: 2015
Contact Information
Address 4000 Shoreline Court, Suite 250, South San Francisco, CA 94080, US
Phone Number (650) 443-7400
Web Address http://www.harpoontx.com
View Prospectus: Harpoon Therapeutics
Financial Information
Market Cap $334.7mil
Revenues $4.4 mil (last 12 months)
Net Income $-22.8 mil (last 12 months)
IPO Profile
Symbol HARP
Exchange NASDAQ
Shares (millions): 5.4
Price range $14.00 - $14.00
Est. $ Volume $75.6 mil
Manager / Joint Managers Citigroup/ SVB Leerink
CO-Managers Canaccord Genuity/ Wedbush PacGrow
Expected To Trade: 2/8/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change